^
Association details:
Biomarker:EGFR positive
Cancer:Lung Cancer
Drug:Erbitux (cetuximab) (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer

Excerpt:
...- Must have positive EGFr expression (tumor tissue) by immunohistochemical assay....
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
Title:

Klinische Studie für Patienten mit einer fortgeschrittenen Lungenkrebserkrankung mit zwei unterschiedlichen Behandlungsmethoden: Cisplatin oder Carboplatin mit Docetaxel in Kombination mit Cetuximab

Excerpt:
...- histologically or cytologically confirmed NSCLC stadium IV UICC 7 - life expectance more than 3 month - ECOG performance status 0 or 1 - positiv EGFR status (IHC score ≥200)...
Less C2 evidence
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Cetuximab-Polymersome-Mertansine Nanodrug for Potent and Targeted Therapy of EGFR-Positive Cancers

Published date:
03/04/2022
Excerpt:
Herein, we constructed a robust cetuximab-polymersome-mertansine nanodrug (C-P-DM1) for highly potent and targeted therapy of epidermal growth factor receptor (EGFR)-positive solid tumors. C-P-DM1 with a...6.0-11.3-fold stronger cytotoxicity in EGFR-positive human breast (MDA-MB-231), lung (A549), and liver (SMMC-7721) cancer cells (IC50 = 27.1-135.5 nM) than P-DM1 control.
DOI:
10.1021/acs.biomac.1c01065